Prolonged ketamine infusion as a therapy for complex regional pain syndrome: Synergism with antagonism? by Pickering, Anthony E. et al.
Commentary
Prolonged ketamine infusion as a therapy for
complex regional pain syndrome: synergism with
antagonism?
Anthony E. Pickering1 & Candida S. McCabe2
1School of Physiology & Pharmacology, University of Bristol, Bristol, UK and 2Faculty of Health and Life Sciences, University of the
West of England, Bristol, UK
Complex regional pain syndrome (CRPS) remains a trou-
bling and often refractory pain condition that typically
develops either following injury to a peripheral nerve (type
II) or following trauma without obvious peripheral nerve
damage (type I). It presents with a characteristic constella-
tion of sensory, motor, autonomic and vascular signs,
within which pain is the central feature. Its aetiology is
uncertain [1], and there is an ongoing debate about
whether it is primarily a neuropathic or an inflammatory/
autoimmune condition [2].
The existing data from treatment trials of conventional
analgesics, antineuropathic pain medications or nerve
blocks have been largely disappointing [3, 4], and much of
the emphasis in treatment is on functional rehabilitation
(see the recent Royal College of Physicians treatment
guidelines [5]). The limitations of existing treatments
means that a substantial cohort of CRPS patients (∼15 000
new cases per year in the UK based on the incidence
figures of de Mos et al. [6]) is left with refractory, long-term
severe pain causing significant disability. Consequently,
there is a need to develop innovative treatment
approaches, such as graded motor imagery, mirror visual
feedback, spinal cord stimulation and transcranial mag-
netic stimulation, all of which have shown some utility in
clinical trials. Set within this context, the review of Niesters
et al. [7] in this issue of BJCP is timely, and articulates the
arguments for a role of prolonged ketamine infusion in the
management of neuropathic pain and specifically for
CRPS.
Ketamine
Ketamine is an anaesthetic drug that has caused polarizing
tumult ever since its successful introduction to clinical
practice in 1970 (reviewed by Domino [8]). Ketamine
immediately found a role in battlefield anaesthesia during
the Vietnam conflict, where its safety (because of relative
lack of cardiorespiratory depressant effects) and its anal-
gesic properties were advantageous. It was the first of the
class of ‘dissociative’ anaesthetic agents and has remained
an integral part of the clinical anaesthetic armamentarium
for emergencies, for paediatrics and as a component
of sedation for invasive medical procedures [9]. Since its
earliest introduction it has also been a drug of abuse, taken
for its hallucinogenic and euphoric actions (like phencycli-
dine). Within this setting, it causes both morbidity (e.g.
bladder pathology) and mortality through overdose-
related aspiration or psychotic delusions leading to self-
harm [10].
The main molecular mechanism of action of ketamine
was uncovered when it was found to be an antagonist at
the NMDA class of glutamate receptor [11]. The NMDA
receptor, then recently identified,was rapidly realized to be
a molecular coincidence detector for neurones (fitting
with the Hebbian postulate), forming a key player in path-
ways for synaptic plasticity, learning and memory [12].
Ketamine is a noncompetitive, use-dependent NMDA
channel blocker that could prevent the induction of syn-
aptic potentiation. It was also subsequently realized that
NMDA receptors play a central role in the processes of
induction and maintenance of pain sensitization, account-
ing for the analgesic efficacy of ketamine [13]. Although
ketamine undoubtedly has actions at other relevant sites,
including nicotinic and opioid receptors, as well as via
monoamine reuptake transporters, it is likely that both the
anaesthetic and the analgesic actions of ketamine are
largely mediated by NMDA receptor antagonism [14]. Like-
wise, the psychototropic and sympatho-excitatory side-
effects of ketamine are also predominantly mediated
through NMDA receptor blockade.
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From its earliest clinical use, there has been consider-
able interest in exploring the therapeutic potential of
ketamine in new territories. It was used experimentally to
model schizophrenia, where its propensity (like phencycli-
dine) to cause hallucinations and delirium was employed
in human studies [15]. The recognition of its neuro-
protective action led industry to use it as a template to
develop other noncompetitive NMDA antagonists to treat
the excitotoxicity of stroke, head injury and also chronic
neurodegenerative conditions [16]. Although animal
studies with pre-emptive administration of these NMDA
antagonists supported a neuroprotective action, the sub-
sequent clinical studies have failed to identify a significant
benefit in most trials. Concerns have also arisen over
potential neurotoxic actions of ketamine seen in some
animal studies. Nonetheless, a similar rationale for the use
of memantine (another noncompetitive NMDA antago-
nist) in Alzheimer’s disease has seen the drug licenced for
clinical use, because it can modify the progression of
dementia [17].
Most recently, ketamine has attracted attention
because it can produce an improvement in depressive
symptoms in man after acute administration [18]. These
antidepressant actions are causing a stir in the field
because of the rapid onset of therapeutic effect (unique
amongst the currently available medications), which may
enable its use as an acute treatment of severe depression.
Reverse translational studies in animals have suggested
that this beneficial effect is the product of rapid synapse
formation (within hours) within the cortex, which reverses
the loss in synapse numbers seen in depression [19].
However, it is thought that ketamine is unlikely to be a
suitable therapeutic agent in the longer-term treatment of
depression because of its challenging pharmacokinetics
and psychotomimetic side-effects.Hence, the search is cur-
rently underway for a better-tolerated NMDA antagonist
that might be as efficacious for long-term administration
in depression [20].
The role of ketamine in pain
management
Ketamine has an established place in the perioperative
management of acute pain (at subanaesthetic doses
<0.5 mg kg−1), where it has consistently been shown to be
opioid sparing and to decrease nausea and vomiting while
adding only a mild side-effect profile of its own [21]. The
S(+) stereoisomer of ketamine has been shown to be twice
as potent as an analgesic (mirroring its greater potency at
the NMDA receptor). Ketamine acts by a distinct, synergis-
tic route to opioids and has also been suggested to attenu-
ate the development of opioid tolerance [22] and perhaps
to prevent opioid-induced hyperalgesia. It therefore has an
accepted role in balanced analgesic regimes and is
deployed in cases where perioperative pain control is likely
to be challenging.
A significant body of evidence has tested the attrac-
tive hypothesis that pre-emptive administration of
ketamine might prevent the development of pain (both
acute and chronic) by preventing the sensitization of
neuronal circuits. Although positive findings were
reported from animal studies, the data from human trials
have not shown a clear pre-emptive benefit [23]. However,
the acute analgesic effects of ketamine can outlast the
expected half-life of the drug, suggesting that there may
indeed be some suppression of neural sensitization in
pain circuits [24].
Ketamine has also been employed in the treatment of
chronic pain (particularly neuropathic pain), where it
shows some short-term efficacy for refractory pain.
However, its utility for chronic pain has been limited by its
pharmacokinetics and side-effect profile. It has relatively
poor bioavailability after oral dosing,and its short duration
of action makes intermittent parenteral dosing impracti-
cal. Additionally, the psychotomimetic profile, nausea and
vomiting, sympatho-activation, effects on cognitive func-
tion allied to risks of misuse and dependence give it a
narrow therapeutic window. This has prompted efforts to
explore the role of other NMDA antagonists with either
better pharmacokinetics or NMDA receptor subtype selec-
tivity, but these efforts have yet to yield a convincing alter-
native therapy. A recent meta-analysis of therapeutics for
neuropathic pain did not find sufficient evidence to
support a role for ketamine or the other NMDA antagonists
[25].
The role of ketamine in the
treatment of complex regional
pain syndrome
Despite these issues, several research groups have under-
taken randomized, controlled trials and published
thought-provoking papers on the use of prolonged
ketamine infusions for treatment of refractory CRPS [26,
27]. These researchers rationalize this approach on the
basis that there may be a longer-lasting resetting of sensi-
tized nociceptive circuits that can outlast the period of
infusion (like that seen in acute pain [24]). The infusions
were maintained at a subanaesthetic level and were either
intermittently dosed over a 10 day period on an outpatient
basis [26] or as a 5 day inpatient protocol [27]. These
studies are credit-worthy because they have produced
interesting affirmative findings and will have been chal-
lenging to undertake in a severe CRPS patient population.
The analysis of these studies suggests that the prolonged
infusions can produce reductions in pain that persist for
weeks. Although issues with the quality of one of these
trials [26] have been raised (see [28]), there would appear
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to be evidence of a substantial (>50%) analgesic effect that
could be worthwhile in refractory cases of CRPS if its dura-
tion could be prolonged.
In a balanced consideration of these trials, it should be
recognized that CRPS is a significant clinical problem with
limited therapeutic options [5, 29]. Any interventions
capable of producing a lasting improvement in pain,motor
function and disability merit serious consideration, and
there are anecdotal reports suggesting that ketamine infu-
sions are being deployed by pain clinicians globally for the
treatment of a variety of pains, including CRPS. This raises
the overarching question of whether this ketamine
therapy can yet be advocated as an evidence-based, cost-
effective, rational, safe and practicable therapy for CRPS.
Recent systematic reviews of treatments for
neuropathic pain have not supported the use of any
NMDA antagonist (e.g. [25]). However, CRPS type I is no
longer considered to be a neuropathic pain syndrome
according to the International Association for the Study of
Pain definition [30]. Prolonged ketamine infusion has been
included in the list of potential therapeutic options for the
management of CRPS in the UK and Dutch guidelines,with
both documents rating the evidence for this treatment as
‘moderate’ or ‘level 3’ [4, 5, 31], but the guidelines conclude
that there is insufficient evidence to commend ketamine
(amongst other drugs) as a part of routine pain clinical
practice for the management of CRPS. This in part reflects
the relatively short-term analgesic benefit and the require-
ment for repeated, prolonged hospital treatment along
with the lack of improvement in affect or in functional
capacity allied to enduring concerns about side-effects.
The beneficial effects of the ketamine infusion on pain
scores are lost by 12 weeks, which must be set against the
chronicity of the disease. Thus, repeated dosing would be
needed for patients with CRPS. For these parenteral infu-
sion protocols, this will require hospitalization and close
observation and will have a cost implication; to date, no
cost–benefit analysis has been published. An additional
complication is that prolonged infusion of ketamine is
known to cause hepatic dysfunction (see review [32]). This
came to lightwhen half of the subjects in a trial of repeated
courses of ketamine infusions for CRPS developed
elevated liver enzymes [33], resulting in the study being
halted early.Although these elevations were slowly revers-
ible, it clearly raises concerns about the safety of repeated
dosing. It is also worth noting that liver toxicity has been
reported in ketamine abusers, and this raises the spectre
that the other side-effects, whether psychotomimetic,
urinary or cognitive, seen in recreational users [10] would
also become problematic in patients undergoing chronic
ketamine treatment (see review [34]).
There is a suggestion from the authors (and see [35])
that prolonged dosing with ketamine may provide a
greater likelihood of therapeutic benefit.This principle has
been somewhat contentiously extended to the territory of
prolonged ketamine coma (involving patients spending
days anaesthetized and ventilated in an intensive care
unit), which its advocates claim to be able to ‘cure’ chronic
neuropathic pain; as yet, this is supported only by case
reports and open-label, uncontrolled trials [36, 37].
Ketamine coma, and indeed oral ketamine and ketamine
combined with nerve block, are cited in the UK Guidance
document under ‘Experimental research’ with insufficient
evidence for their efficacy at present (Goebel et al. 2012)
and are not included in the Dutch guidelines [31]. There
are few centres or clinicians that would offer (on the avail-
able evidence) this as a reasonable therapeutic approach
to the management of CRPS.
This need for chronic NMDA antagonist dosing also
raises the issue of whether parenteral ketamine is the
optimal drug for this purpose. An oral lozenge prepara-
tion of ketamine has been shown to have adequate
pharmacokinetics [38] but is as yet unproven in any pain
trial.Other studies of dosingwith other NMDA antagonists,
such as memantine and amantadine, have failed to show
beneficial effects alone [3, 4]. Case reports and a single
study have reported some utility when memantine is used
in combination with morphine and physical rehabilitation
[39, 40], although this may reflect an opiate-sparing effect
or the benefit of physiotherapy techniques, rather than an
analgesic action in its own right.
The apparent comparative lack of effectiveness of
these other NMDA antagonists in CRPS may relate to their
lower efficacy as antagonists or may also indicate that the
ketamine is acting via another molecular mechanism.
Niesters et al. [7] have started to investigate this possibility
further, looking at influences on endogenous pain modu-
lation and in imaging studies. Ketamine administration
produces brain activity in areas that are part of pain
modulation circuitry, such as the anterior cingulate, the
insula and the brainstem, and in the same study they also
report an increase in conditioned pain modulation in
behaviour studies in volunteers (although they have also
previously reported a suppression of another endogenous
analgesic mechanism by ketamine, [41]). These effects
could potentially also be mediated via the opioidergic or
monoaminergic reuptake action of ketamine. Such actions
to engage/modulate endogenous analgesia might also
help to account for the long-duration ketamine effect, as
this could potentially be self-reinforcing.
One of the most striking features of the ketamine infu-
sion studies is the lack of improvement of mood or func-
tion despite the improvement in pain scores. This is
surprising given the recent realization that ketamine
exerts an antidepressant action [18]. It also runs counter to
the belief that the functional deficits in CRPS are exclu-
sively secondary to pain. This is more consistent with the
idea that the motor disturbance is a separate pathological
entity. It is perhaps also relevant that acute ketamine
dosing is known to cause ataxia and motor impairment.
Importantly, the current guidelines for the management
of CRPS recommend an integrated interdisciplinary ap-
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proach to the patient’s care, which aims to reduce pain,
restore function and improve quality of life [5,29,42]. Func-
tional rehabilitation is at the centre of the care pathway
and should be facilitated by education/self-management
strategies, psychological and pharmacological support.
Specifically, the risk–benefit profile of pharmacological
interventions should be considered to ensure that they do
not compromise engagement with functional rehabilita-
tion, as for example, the excessive drowsiness that can be
seen with opioids. Both of these ketamine infusion studies
had cohorts with long disease durations, and therefore,
secondary psychosocial consequences of pain are likely to
have been prevalent. Future research is warranted to
establish what additional benefit ketamine could provide
within a multidisciplinary rehabilitation model with
administration earlier in the disease progression.
Administering ketamine as an adjunct tophysical thera-
pies may also be advantageous (besides its analgesic
action) because of the potential for increased cortical syn-
aptic plasticity being ascribed to NMDA antagonists from
the depression field. Notably, memantine was reported to
facilitate reversal of cortical reorganization (in one subject)
of the primary somatosensory map representing the
painful CRPS limb [40].Similar reports have been described
for amputee phantom limb pains when memantine has
been administered [43]. It is well established in phantom
limb pains and CRPS that there is a correlation between
levels of perceived pain intensity and the extent of cortical
reorganization,withpain reducingas corticalmapsnormal-
ize [43, 44]. Changes in the primary sensory and motor
maps in CRPS are thought to contribute to disruptedmotor
planning, altered sensory perceptions, referred sensations
and body perception disturbances (see [45] for review).
All of these clinically observed problems have shown some
improvement with nonpharmacological strategies that
have targeted correction,but perhaps these benefits could
be further enhanced in the presence of NMDA antagonists.
The ketamine infusion studies have provided evidence
of a clinically meaningful (albeit transitory) analgesic
benefit; something that is all too rare in the pharmaco-
logical management of CRPS. However, the challenges
posed by its pharmacokinetics and risk profile remain.The
prospects for achieving similar outcomes using (hope-
fully) safer, more convenient, subtype-selective NMDA
antagonists remains on the horizon [14, 46], but for the
present we have little evidence for effective alternatives.
Perhaps we will need a change of mind set to consider the
management of CRPS with ketamine as being akin to the
management of cancer with chemotherapy, i.e. toxic, but if
the outcome is sufficiently positive then it may justify the
risks. To arrive at this point, we would need multicentre,
randomized, controlled trials comparing best current
management with/without ketamine infusion with long-
term follow-up and outcomes (as per IMMPACT guideline
[47]) judged on the basis of remission and survivor analy-
sis balanced against the toxicity. The situation is therefore
similar for other potential new therapies, such as spinal
cord stimulation or intravenous immunoglobulins; a
balance of risk vs. benefit. The evidence discussed above
indicates that even after 40 years the ketamine tiger (to
paraphrase Domino [8]) remains potent and still has teeth
that merit a cautious approach to its use in the manage-
ment of chronic pain.
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